



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Quantification of Mesenchymal Stem Cell (MSC) Delivery to a Target Site Using In Vivo Confocal Microscopy

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

Citation	Mortensen, Luke J., Oren Levy, Joseph P. Phillips, Tara Stratton, Brian Triana, Juan P. Ruiz, Fangqi Gu, Jeffrey M. Karp, and Charles P. Lin. 2013. "Quantification of Mesenchymal Stem Cell (MSC) Delivery to a Target Site Using In Vivo Confocal Microscopy." PLoS ONE 8 (10): e78145. doi:10.1371/journal.pone.0078145. http://dx.doi.org/10.1371/journal.pone.0078145 .
Published Version	doi:10.1371/journal.pone.0078145
Accessed	February 19, 2015 2:53:10 PM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879164
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)

Quantification of Mesenchymal Stem Cell (MSC) Delivery to a Target Site Using In Vivo Confocal Microscopy

Luke J. Mortensen¹, Oren Levy², Joseph P. Phillips², Tara Stratton¹, Brian Triana¹, Juan P. Ruiz², Fangqi Gu², Jeffrey M. Karp², Charles P. Lin^{1*}

1 Wellman Center for Photomedicine and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, **2** Center For Regenerative Therapeutics & Department of Medicine Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts, United States of America

Abstract

The ability to deliver cells to appropriate target tissues is a prerequisite for successful cell-based therapy. To optimize cell therapy it is therefore necessary to develop a robust method of in vivo cell delivery quantification. Here we examine Mesenchymal Stem Cells (MSCs) labeled with a series of 4 membrane dyes from which we select the optimal dye combination for pair-wise comparisons of delivery to inflamed tissue in the mouse ear using confocal fluorescence imaging. The use of an optimized dye pair for simultaneous tracking of two cell populations in the same animal enables quantification of a test population that is referenced to an internal control population, thereby eliminating intra-subject variations and variations in injected cell numbers. Consistent results were obtained even when the administered cell number varied by more than an order of magnitude, demonstrating an ability to neutralize one of the largest sources of in vivo experimental error and to greatly reduce the number of cells required to evaluate cell delivery. With this method, we are able to show a small but significant increase in the delivery of cytokine pre-treated MSCs (TNF- α & IFN- γ) compared to control MSCs. Our results suggest future directions for screening cell strategies using our in vivo cell delivery assay, which may be useful to develop methods to maximize cell therapeutic potential.

Citation: Mortensen LJ, Levy O, Phillips JP, Stratton T, Triana B, et al. (2013) Quantification of Mesenchymal Stem Cell (MSC) Delivery to a Target Site Using In Vivo Confocal Microscopy. *PLoS ONE* 8(10): e78145. doi:10.1371/journal.pone.0078145

Editor: Irene Georgakoudi, Tufts University, United States of America

Received: May 9, 2013; **Accepted:** September 9, 2013; **Published:** October 29, 2013

Copyright: © 2013 Mortensen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors would like to acknowledge Sanofi for funding to support this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors would like to declare the commercial funding source "Sanofi S.A." and confirm that the funding source does not alter their adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: charles_lin@hms.harvard.edu

Introduction

Cell-based therapeutics offer the potential to address unmet clinical needs in which traditional health care has faltered. Cellular therapies have been explored in pre-clinical and clinical models, and demonstrated promise in diseases such as lung injury [1], myocardial infarction [2,3], graft versus host disease [4,5], and sepsis [6]. However, very few clinical applications have been approved so far, which suggests that treatment efficacy could be improved. One of the primary strategies to improve therapeutic outcome is by increasing delivery of cells to their target tissue. To do so, methods such as alternative culture [7,8], pretreatment with cytokines [9,10,11], transfection [12,13,14], or cell engineering [15,16,17,18] have been used. Our lab has primarily focused on cell surface engineering of therapeutic mesenchymal stem cells (MSCs), and has found that functionalization of the MSC surface can enhance their delivery to an inflamed site in vivo [18].

To evaluate the delivery of potential cell therapeutics in vivo, the most common techniques are radiolabeling [19,20], bioluminescence [21,22,23,24], fluorescent protein expression [25,26,27,28,29], and exogenous fluorescence labels [17,18,30,31]. Of these, only fluorescent protein expression and exogenous fluorescence labeling have been demonstrated to have adequate sensitivity for single cell detection in vivo. Fluorescent protein expression is a powerful technique when purification of

cells from transgenic mice or transfection using lentivirus is possible. However, transfection can yield variable fluorescent protein expression [32,33] and impact cell function [34], and as such is not optimal for all applications. Therefore, to track cell delivery to inflamed tissues, we stain the cell membrane with lipophilic membrane dyes and image the cells in vivo using confocal microscopy. Single cell detection using confocal microscopy allows dynamic and quantitative tracking of cells in vivo, an important capability in the evaluation of cell modification strategies and elucidation of biological mechanisms. Previously published research by our group and others has demonstrated the usefulness of this strategy to evaluate the impact of cell surface engineering in vivo using MSCs. In particular, studies by Sackstein et al. and Sarkar et al. found that surface engineering of MSCs stained with lipophilic membrane dyes enhanced delivery to the bone marrow via enzymatic modification and to the inflamed ear via Sialyl Lewis^x chemical modification, respectively [18,30].

One significant advantage of fluorescent cell labels is the ability to detect multiple colors at once, a strategy leveraged by Sarkar et al. When combined in an optimized dye pair, simultaneously administered modified and control cells can be quantified, which allows each animal to serve as its own control and limits animal-to-animal variability. The aim of this study is to select the optimal dye

pair combination from a series of 4 membrane stains for quantifying cell delivery to inflamed tissue using MSCs by elucidating the practical optical characteristics of each cell tracking dye from visible to near-IR emission. Our results will improve the ability of researchers to quantify and optimize in vivo cell homing behavior.

Results and Discussion

In Vitro MSC Staining and Viability

To determine the relative staining efficiency in vitro, stained MSCs were mixed in equal quantities at 10^6 cells/mL for each color, imaged on a glass slide, and displayed simultaneously (Fig. 1a). In each frame, all MSCs were stained as determined by comparison with the reflectance channel. Quantification of cell numbers ($n \approx 100$ for each color, from a total of ~ 20 fields of view) shows that about equal number of cells are detected in each color (Fig. 1b). Direct insertion of the dyes into the cell membrane had a limited impact on viability versus the unstained control ($p < 0.05$, Tukey's HSD) as measured by metabolic activity using MTS with minimal difference between stains ($\sim 80\%$ of unstained for all, Fig. 1c).

MSC Trafficking to Inflamed Ears

To evaluate the performance of lipophilic dyes for use in quantifying cell delivery to an inflamed site, 7×10^4 MSCs stained with each of the range of dyes were systemically infused. By imaging in the inflamed ear, cells labeled with all four stains can be visualized, as displayed using a maximum intensity projection of the 3D stacks (Fig. 2a). Cell counting was performed on individual channels in the 3D stack with contrast enhanced to enable detection of all events, after first excluding autofluorescent cells which typically showed up as low-intensity objects distributed across than one channels. Upon quantification (Fig. 2b), a difference between the detected number of cells for the stains was observed ($p < 0.05$, 1-way ANOVA). The largest number of MSCs were detected with DiI staining (168 ± 16 cells/mm²), followed by DiD (144 ± 11 cells/mm²), DiO (128 ± 11 cells/mm²) and DiR (103 ± 14 cells/mm²). Higher tissue autofluorescence background at shorter wavelengths likely contributed to the lower sensitivity for DiO. Interestingly, the advantages of diminished autofluorescence and better tissue penetration with increasing wavelength did not lead to higher cell counts for DiR, most likely due to the reduced quantum efficiency of our PMTs at wavelengths > 700 nm. These results suggest that in terms of detected counts in the inflamed ear, the optimal dye pair for future use is DiI and DiD.

Depth Dependence of Detection

To better characterize how the detection sensitivity varies with wavelength, we next evaluated the depth dependence of detection for the range of MSC stains. This depth distribution of detected cells is a function of the staining intensity, the detection sensitivity of the system at the wavelength of interest, and the scattering properties of the tissue at the excitation/emission wavelengths. Interestingly, little difference can be observed between the cell colors in the depth histogram shape and mean depth (Fig. 3a). Since our LPS injection is in the subcutaneous space on one side of the ear (mouse ears are ~ 200 μm in thickness with collagen support in the center), it is likely that the average depth of detected MSCs of 58 μm is the actual location of the cells. This suggests that the majority of the cells are located at depths sufficiently shallow to be detected regardless of the stain. However, if only the deepest cells are investigated (> 100 μm deep), an increase in the proportion of detected cells is observable with increasing dye emission wavelength (Fig. 3a), which is expected due to the decreased scattering and absorption at longer wavelengths. Additionally, if MSC intensity is examined as a function of depth and normalized to the brightest cells, an increase in intensity for the longest wavelength DiR stained cells is found at the deepest locations (Fig. 3b). This result is supported by a simple model prediction based on scattering and absorption coefficients reported in the literature for mouse ears with our excitation and peak emission wavelengths [35]. To do so, we used the formula.

$$I = e^{-z(\mu'_{s-in} + \mu_{a-in} + \mu'_{s-out} + \mu_{a-out})}$$

where the relative signal intensity (I) is a function of depth (z , mm), reduced scattering coefficient for excitation (μ'_{s-in} , mm⁻¹) and emission (μ'_{s-out} , mm⁻¹), and absorption coefficient for excitation (μ_{a-in} , mm⁻¹) and emission (μ_{a-out} , mm⁻¹). At a depth of 135 μm , this approximation would suggest a remaining intensity of 29% for DiO, 31% for DiI, 38% for DiD, and 44% for DiR. Our experimental results at 135 μm align well with predicted values ($31 \pm 9\%$ for DiO, $39 \pm 9\%$ for DiI, $42 \pm 20\%$ for DiD, and $54 \pm 20\%$ for DiR), but with increased error due to the small number of cells that are found at 135 μm depth. These results suggest future work to more carefully investigate contributing factors to accurately model our imaging scheme and determine relative contributions of all optical and electronic parameters [36]. Since DiI and DiD exhibited the highest intensity and counts, this dye pair was selected for subsequent experimentation.




Figure 1. MSC staining in vitro. In vitro imaging characteristics of MSCs stained with lipophilic membrane dyes (a). Mixing equal quantities of the cells yielded similar levels of detected cells (b). Despite a small decrease in viability from the unstained control ($p < 0.05$, Tukey's HSD), there was minimal difference between viability of cells after staining as measured by MTS (c). Scale bar = 100 μm . doi:10.1371/journal.pone.0078145.g001




Figure 2. MSC delivery to an inflamed site in vivo. Intravenously infused MSCs stained with a range of lipophilic membrane dyes appear in the inflamed ear 24 h after administration. High numbers of MSCs are present in the inflamed ear for each color (a). A stain-dependent difference in detected cell numbers was found ($p < 0.05$, 1-way ANOVA), where DiI and DiD yielded the highest counts in the ear with DiO and DiR having relatively fewer cells detected (b). Scale bar = 100 μm .
doi:10.1371/journal.pone.0078145.g002

Detection of Increased MSC Homing with Cytokine Pre-treatment

One strategy to increase the delivery of MSCs to diseased sites is to pre-treat the cells with a small molecule or cytokine that will up-regulate or activate homing mechanisms of the MSC. As a proof of concept to demonstrate the usefulness of our optimized DiD/DiI dye pair in evaluating MSC homing to the inflamed ear, a cytokine cocktail of TNF- α & IFN- γ was used. Both molecules are well accepted to activate MSC function and homing [37,38,39,40], and were introduced to the cell media in vitro 24 h before infusion (10 ng/mL each). Use of a dye switch with correction for the dye efficiency as described in the materials and methods section allowed direct comparison between the numbers of MSCs detected in the inflamed ear. As shown in Fig. 4a,b, a statistically significant increase of $22 \pm 2\%$ was found in the delivery of TNF- α /IFN- γ -treated MSCs to the inflamed site as compared to the control MSCs ($p < 0.05$, unpaired Students t-test). The effect remained with a commensurate reduction in detected cell counts ($p < 0.05$, 2-way ANOVA) when progressively fewer cells were systemically infused from 5×10^5 cells down to 1×10^4 cells, which is highlighted by plotting the average ratio of pre-treated MSCs to control MSCs in the inflamed ear at each dose (Fig. 4c,d). An increase in cell delivery this small would likely remain undetected if only a single cell population was analyzed per mouse (i.e. without the co-infusion of treated and control cells labeled with the DiI/DiD dye pair) due to variability among individual animals that could result from parameters such as cell infusion number and the severity of inflammation. These results indicate the power of our technique to neutralize one of the largest sources of in vivo experimentation variability, and build on a previous report demonstrating a larger enhancement of MSC trafficking to inflamed sites [18]. Additionally, validating the injection of significantly fewer cells than the 1×10^6 per mouse or more commonly used to analyze homing behavior, substantially reduces experimentation burden allows more efficient testing of cell delivery strategies, and more closely mimics cell loading used in human clinical trials [10,17,18,19,21,28,41]. To further increase the throughput potential of our validated inflamed ear quantification technique, future work will pursue automation of

cell counting by tailoring techniques described in published cell counting studies [42,43,44] to the high background imaging environment of the skin.

Conclusions

This work demonstrates an optimized corrected dye pair to generate robust quantification of cell delivery to target the inflamed mouse ear using primary human MSCs. We have shown that a range of lipophilic membrane dyes yield consistent staining in vitro and in vivo, and have minimal impact on viability in vitro. We have determined that the bulk of MSCs detected in the dermal layers of the skin appear to be within 55–60 μm of depth, that longer wavelength dyes allow detection of higher numbers of cells deep in the tissue, and the optimal nature of the DiI/DiD dye pair in our system. To apply our findings, we demonstrated increased homing that was consistent across cell injection number for MSCs pretreated with TNF- α /IFN- γ , with use of a dye ratio to correct for injection number and provide a robust quantification of homing improvement. Our optimized assay was able to detect a small increase in cell delivery, and could improve experimental throughput in the future by substantially reducing the number of cells needed for investigation of cell engineering strategies. This knowledge can be used to determine the efficacy of further cell engineering approaches to improve cell trafficking to target tissue, and may help yield novel therapeutics and cell delivery strategies in the future.

Materials and Methods

Cell Staining and Viability

To allow tracking of MSCs, cells were stained with a range of lipophilic membrane dyes with emission wavelengths in the green (DiO, extinction coefficient = $154,000 \text{ cm}^{-1}\text{M}^{-1}$ in MeOH), red (DiI, extinction coefficient = $148,000 \text{ cm}^{-1}\text{M}^{-1}$ in MeOH), far red (DiD, extinction coefficient = $193,000 \text{ cm}^{-1}\text{M}^{-1}$ in MeOH), and near-IR (DiR, extinction coefficient = $270,000 \text{ cm}^{-1}\text{M}^{-1}$ in MeOH) (Invitrogen, Carlsbad, CA). Primary human MSCs were suspended at a concentration of 10^6 cells/mL and incubated with




Figure 3. Stained MSC depth detection dependence. When the depth dependence of detection for MSCs dyed with each stain is analyzed, no discernable difference in the depth histogram or in the average MSC depth is observable (a). However, a modest increase in the number of MSCs detectable below the depth of $100 \mu\text{m}$ appears with longer wavelength dyes. Normalized intensity of cells analyzed over depth indicates a close match between experimental results and theoretical predictions, with an improvement in the intensity retention of the near-IR emitting DiR labeled cells (b). Average signal intensity revealed a lower intensity for DiO- likely due to high background near the skin surface and signal degradation at greater depth- and for DiR. However, DiR intensity was mostly recovered when corrected for detector quantum efficiency, suggesting the importance of detector characteristics in cell detection.
doi:10.1371/journal.pone.0078145.g003




Figure 4. An optimized dye pair allows quantification of MSC cytokine pre-treatment impact on delivery to an inflamed site. Systemic infusion of MSCs pretreated with TNF- α /IFN- γ (blue, stained with Vybrant DiD) increases cell trafficking to the inflamed ear vs. control MSCs (green, stained with Vybrant DiI) (a). When quantified, this yields an average increase in cells/mm² of ear surface area of 22 \pm 2% ($p < 0.05$, Students unpaired t-test) (b). The increase in trafficking is of a consistent magnitude across a range of injected cell numbers with a commensurate range of detected counts ($p < 0.05$, 2-way ANOVA) (c). If the increase in homing for each cell dose is plotted, consistent evaluation of the homing increase is observed, even with a wide range of injected cell numbers (d). Scale bar = 100 μ m. doi:10.1371/journal.pone.0078145.g004

10 μ M Vybrant DiO, 10 μ M Vybrant DiI, 10 μ M Vybrant DiD, or 15 μ M Vybrant DiR in 1 \times PBS+0.1% BSA for 20 minutes at 37°C. The MSCs were then washed twice in 1 \times PBS and mixed in equal numbers for imaging in vitro or in vivo at a concentration of 1 \times 10⁷ cells/mL. To investigate the impact of lipophilic membrane stains on MSC health, cell viability was tested using the metabolic activity stain MTS according to standard protocols. Equal numbers of the stained MSCs were placed in individual wells in triplicate and incubated 24 h in media at 37°C. The formazan-based reagent was added for 4 h and viability was assessed by absorbance at 590 nm.

In Vivo MSC Homing

C57BL/6 mice (Charles River Laboratories, Wilmington, MA) were anesthetized with ketamine/xylazine and their ears shaved 24 h prior to cell infusion. To induce an inflammatory response, 30 μ g of *E. coli* lipopolysaccharide (LPS, Sigma, St. Louis, MO) in 50 μ L saline was injected into the pinna of the left ear, with 50 μ L 0.9% saline injected into the right ear as a control. For in vivo dye sensitivity validation, 70,000 cells of each stain were suspended in 150 μ L PBS (pH 7.4) and injected by retro-orbital vein infusion. Studies were in accordance with US National Institutes of Health guidelines for care and use of animals under approval of the Institutional Animal Care and Use Committees of Massachusetts General Hospital and Harvard Medical School.

To evaluate the impact of cytokine pre-treatment of MSC homing to the inflamed ear, MSCs were incubated with 10 ng/mL each of TNF- α and IFN- γ for 24 h before staining and in vivo administration. Each mouse ($n = 4$) received a range of cell doses (1 \times 10⁴, 5 \times 10⁴, 1 \times 10⁵, or 5 \times 10⁵) each of cytokine pre-treated cells and control cells stained with DiI or DiD with a dye switch. To highlight the vasculature, 50 μ L of 10 mg/mL FITC-dextran (2 \times 10⁹ kDa; Sigma, St. Louis, MO) was injected retro-orbitally prior to imaging.

Confocal Fluorescence Microscopy

In vitro staining and in vivo homing of stained MSCs to the skin was imaged noninvasively in real time using a custom-built video-rate laser-scanning confocal microscope [45]. For this work, the microscope assembly was expanded to allow the acquisition of 4 fluorescence confocal channels simultaneously. To image cell staining efficiency in vitro, equal numbers of MSCs stained with each of the dyes were mixed and placed on a microscope slide with a coverslip at a concentration of 10⁶ cells/mL. For in vivo imaging, the mouse ear was positioned under a coverslip with methylcellulose gel and images acquired at 30 frames per second at a depth up to 200 μ m using a 60X 1.0NA water immersion objective lens (Olympus, Center Valley, PA). DiO labeled MSCs were excited with a 491 nm continuous wave (CW) laser (Cobalt, Stockholm, Sweden), and detected through a 520 \pm 20 nm

bandpass filter (Semrock, Inc., Rochester, NY). DiI labeled MSCs were excited with a 561 nm CW laser (Coherent, Inc., Santa Clara, CA) and detected through a 593 nm \pm 40 nm filter (Omega Optical, Brattleboro, VT). DiD labeled MSCs were excited with a 638 nm CW laser (Coherent, Inc., Santa Clara, CA) and detected through a 695 nm \pm 27.5 nm band pass filter (Omega Optical, Brattleboro, VT). DiR labeled MSCs were excited using a femtosecond Ti:Sapphire Maitai source for single photon excitation at 750 nm (Spectra Physics, Santa Clara, CA) and collected through a 785 nm \pm 31 nm band pass filter (Omega Optical, Brattleboro, VT).

Quantification with Dye Switch

For quantification, the average number of cells in 20 representative imaging locations across the inflamed region were counted in each mouse. Cells were defined as having a diameter from 10–30 μ m to eliminate debris and clumps from analysis, and a primary channel intensity greater than 2 to eliminate auto-fluorescent events. To ensure accurate quantification of MSC homing to the inflamed ear, the optimal dye pair was selected as described above and used with a dye switch. In this, half of the test animals received a solution containing DiI control cells and DiD TNF- α /IFN- γ treated cells. The other half of the test animals receive a solution containing DiD control cells and DiI TNF- α /IFN- γ cells. The counts for DiD cells were adjusted by the relative

detection sensitivity (ratio of DiI/DiD counts) determined in the overall dye efficiency experiments (Fig. 2b). This dye switch allowed direct comparison of cell homing numbers and ensured that equalization did not introduce bias into our measurements.

Statistical Analysis

For individual pairwise comparisons, an unpaired two-tailed Student's t-test was used. For group analyses, 1-way or 2-way ANOVA was used, with Tukey's HSD to evaluate multiple pairwise comparisons. Error bars in all graphs represent standard deviation, and statistical significance is denoted by * p <0.05.

Acknowledgments

We would like to thank our collaborators at Sanofi. Jean-Francois Deleuze, Gerald Boquet, Christelle Perrault, and Brigitte Benhamou all provided valuable support and discussion on this research. We would also like to thank Kyle Tsang and Lara (Moyu) Fu for assistance with cell culture and preparation.

Author Contributions

Conceived and designed the experiments: LJM OL JPP JMK CPL. Performed the experiments: LJM OL JPP TS BT JPR FG. Analyzed the data: LJM TS BT JPR FG. Contributed reagents/materials/analysis tools: LJM OL JMK CPL. Wrote the paper: LJM OL JMK CPL.

References

- Ortiz LA, DuTrell M, Fattman C, Pandey AC, Torres G, et al. (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proceedings of the National Academy of Sciences* 104: 11002–11007.
- Mangi AA, Noiseux N, Kong D, He H, Rezvani M, et al. (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. *Nat Med* 9: 1195–1201.
- Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, et al. (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. *Cell Stem Cell* 5: 54–63.
- Prasad VK, Lucas KG, Kleiner GI, Talano JAM, Jacobsohn D, et al. (2011) Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (ProchymalTM) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. *Biol Blood Marrow Transplant* 17: 534–41.
- von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, et al. (2011) Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy. *Biol Blood Marrow Transplant*.
- Németh K, Leelahavanichkul A, Yuen PST, Mayer B, Parmelee A, et al. (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 15: 42–9.
- Hung S, Pochampally RR, Hsu S, Sanchez C, Chen S, et al. (2007) Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. *PLoS One* 2: e416.
- Bartosh TJ, Ylostalo JH, Mohammadipoor A, Bazhanov N, Coble K, et al. (2010) Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. *Proc Natl Acad Sci U S A* 107: 13724–9.
- Segers VF, Van Riet I, Andries LJ, Lemmens K, Demolder MJ, et al. (2006) Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. *Am J Physiol Heart Circ Physiol* 290: 1370–1377.
- Shi M, Li J, Liao L, Chen B, Li B, et al. (2007) Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. *Haematologica* 92: 897–904.
- Deuse T, Peter C, Fedak PWM, Doyle T, Reichenspurner H, et al. (2009) Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. *Circulation* 120: S247–54.
- Han JY, Goh RY, Seo SY, Hwang TH, Kwon HC, et al. (2007) Cotransplantation of cord blood hematopoietic stem cells and culture-expanded and GM-CSF-/SCF-transfected mesenchymal stem cells in SCID mice. *J Korean Med Sci* 22: 242–247.
- Min C, Kim B, Park G, Cho B, Oh I (2007) IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. *Bone Marrow Transplant* 39: 637–45.
- Choi J, Yoo S, Park S, Kang Y, Kim W, et al. (2008) Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. *Clin Exp Immunol* 153: 269–76.
- Sarkar D, Vemula PK, Zhao W, Gupta A, Karnik R, et al. (2010) Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. *Biomaterials* 31: 5266–74.
- Sarkar D, Ankrum JA, Teo GS, Carman CV, Karp JM (2011) Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. *Biomaterials* 32: 3053–3061.
- Zhao W, Schafer S, Choi J, Yamanaka YJ, Lombardi ML, et al. (2011) Cell-surface sensors for real-time probing of cellular environments. *Nat Nanotechnol* 6: 524–31.
- Sarkar D, Spencer JA, Phillips JA, Zhao W, Schafer S, et al. (2011) Engineered cell homing. *Blood* 118: e184–e191.
- Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 169: 12–20.
- Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, et al. (2003) Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. *Circulation* 108: 863–868.
- Dégano IR, Vilalta M, Bagó JR, Matthies AM, Hubbell JA, et al. (2008) Bioluminescence imaging of calvarial bone repair using bone marrow and adipose tissue-derived mesenchymal stem cells. *Biomaterials* 29: 427–37.
- Wang H, Cao F, De A, Cao Y, Contag C, et al. (2009) Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. *Stem Cells* 27: 1548–1558.
- Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, et al. (2009) Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. *Stem Cells* 27: 2614–23.
- Ko IK, Kim B, Awadallah A, Mikulan J, Lin P, et al. (2010) Targeting improves MSC treatment of inflammatory bowel disease. *Mol Ther* 18: 1365–72.
- Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, et al. (2003) Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. *J Gene Med* 5: 1028–38.
- Rombouts WJC, Ploemacher RE (2003) Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. *Leukemia* 17: 160–70.
- Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 466: 829–34.
- Joo S, Cho K, Jung Y, Kim H, Park S, et al. (2011) Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction. *Cell Biol Int* 35: 417–21.

29. Park D, Spencer JA, Koh BI, Kobayashi T, Fujisaki J, et al. (2012) Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. *Cell Stem Cell* 10: 259–272.
30. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, et al. (2008) Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. *Nat Med* 14: 181–7.
31. Lin YC, Leu S, Sun CK, Yen CH, Kao YH, et al. (2010) Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. *J Transl Med* 8: 88–88.
32. Sigal A, Milo R, Cohen A, Geva-Zatorsky N, Klein Y, et al. (2006) Variability and memory of protein levels in human cells. *Nature* 444: 643–6.
33. Halter M, Tona A, Bhadriraju K, Plant AL, Elliott JT (2007) Automated live cell imaging of green fluorescent protein degradation in individual fibroblasts. *Cytometry A* 71: 827–34.
34. Haccin-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, et al. (2003) A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency. *New England Journal of Medicine* 348: 255–256.
35. Salomatina E, Yaroslavsky AN (2008) Evaluation of the in vivo and ex vivo optical properties in a mouse ear model. *Physics in Medicine and Biology* 53: 2797.
36. Mortensen IJ, Glazowski CE, Zavislan JM, Delouise LA (2011) Near-IR fluorescence and reflectance confocal microscopy for imaging of quantum dots in mammalian skin. *Biomed Opt Express* 2: 1610–1625.
37. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, et al. (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. *Eur J Immunol* 38: 1745–55.
38. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, et al. (2008) Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. *Am J Physiol Cell Physiol* 294: C675–82.
39. Liu Y, Wang L, Kikui T, Akiyama K, Chen C, et al. (2011) Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. *Nat Med* 17: 1594–601.
40. Prockop DJ, Youn Oh J (2012) Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation. *Mol Ther* 20: 14–20.
41. Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the details. *Cell Stem Cell* 4: 206–16.
42. Ancin H, Roysam B, Dufresne TE, Chestnut MM, Ridder GM, et al. (1996) Advances in automated 3-D image analyses of cell populations imaged by confocal microscopy. *Cytometry* 25: 221–234.
43. Lin G, Adiga U, Olson K, Guzowski JF, Barnes CA, et al. (2003) A hybrid 3D watershed algorithm incorporating gradient cues and object models for automatic segmentation of nuclei in confocal image stacks. *Cytometry A* 56: 23–36.
44. Forero MG, Hidalgo A (2011) Image Processing Methods for Automatic Cell Counting In Vivo or In Situ Using 3D Confocal Microscopy.
45. Veilleux I, Spencer JA, Biss DP, Cote D, Lin CP (2008) In Vivo Cell Tracking With Video Rate Multimodality Laser Scanning Microscopy. *Selected Topics in Quantum Electronics, IEEE Journal of* 14: 10–18.